With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer
Regulatory News:
This Pancreatic Cancer Awareness Month, Mauna Kea Technologies (Euronext Growth: ALMKT),the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is raising awareness about one of the deadliest cancers by sharing patient stories and emphasizing the importance of early detection.
With a five-year survival rate of just 13% and rising diagnoses among individuals under 50, urgent action is required to increase public knowledge and promote the use of advanced diagnostic tools. A recent survey reveals that 83% of people cannot identify early symptoms of pancreatic cancer, such as persistent abdominal or back pain, sudden-onset diabetes, unexplained weight loss, or jaundice. These findings highlight a critical gap in awareness, especially given the subtle and easily overlooked nature of these signs.
To address this disease, Mauna Kea Technologies is sharing stories of patients whose lives were transformed through timely diagnosis and innovative tools like the Cellvizio platform at The Ohio State University Wexner Medical Center.
Discover these inspiring journeys and learn more about pancreatic cancer symptoms by visiting this page. These stories underline the profound impact of early detection tools like Mauna Kea Technologies' Cellvizio, which allows real-time cellular imaging during endoscopic procedures. Cellvizio plays a pivotal role in accelerating accurate diagnoses, especially for patients at high risk or with indeterminate pancreatic cysts.
As part of its mission to improve patient care, Mauna Kea Technologies continues to collaborate with healthcare professionals and researchers worldwide to advance endomicroscopy and other diagnostic innovations.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2023 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2024, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126981077/en/
Contacts:
Mauna Kea Technologies
investors@maunakeatech.com
NewCap Investor Relations
Aurélie Manavarere Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu
